Skip to content

US · RGC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Regencell Bioscience Holdings Limited (RGC) intrinsic value and stock valuation

$4.18as of 2026-11-21 · Mkt cap 2.91B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Regencell Bioscience Holdings Limited DCF and intrinsic value

InvestorsCraft values RGC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RGC’s statements →

Regencell Bioscience Holdings Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Hong Kong KY1-1107 regencellbioscience.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-3.58M
20192025
Free cash flow
-$-3.27M
20192025
Total equity
$4.86M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-3.77M-$-4.74M-$-6.27M-$-7.62M-$-1.38M
Net income-$-3.58M-$-4.3M-$-5.87M-$-7.42M-$-1.35M
EPSd-$-7.24K-$-8.7K-$-11.87K-$-15.01K-$-2.81K
Operating cash flow-$-3.11M-$-4M-$-4.96M-$-5.27M-$-770K
Capital expenditure-$-150K-$-10K-$-30K-$-780K$0.00
Free cash flow-$-3.27M-$-4.01M-$-4.99M-$-6.05M-$-770K
Total assets$5.76M$8.44M$12.6M$18M$340K
Total debt$540K$90K$460K$770K$3.68M
Net debt-$-1.87M-$-2.88M-$-1.1M-$-5.65M$3.62M
Total equity$4.86M$8.22M$12M$17.1M-$-4M
Cash and short-term investments$4.9M$7.96M$11.6M$16.4M$60K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$390K$750K$770K$600K$30K
Gross profit-$-390K-$-750K-$-770K-$-600K-$-30K
Research and development expenses$950K$1.07M$1.58M$2.51M$440K
Selling, general and administrative expenses$2.43M$2.92M$4.69M$5.11M$940K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.38M$3.99M$6.27M$7.62M$1.38M
Cost and expenses$3.77M$4.74M$6.27M$7.62M$1.38M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$390K$750K$770K$600K$30K
Ebitda-$-3.19M-$-3.62M-$-5.29M-$-6.99M-$-1.35M
Operating income-$-3.77M-$-4.74M-$-6.27M-$-7.62M-$-1.38M
Total other income/expenses, net$190K$370K$210K$20K$30K
Income before tax-$-3.58M-$-4.36M-$-6.06M-$-7.59M-$-1.35M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.58M-$-4.3M-$-5.87M-$-7.42M-$-1.35M
Weighted average shares outstanding$494.5M$494.5M$494.5M$494.5M$480.4M
Weighted average diluted shares outstanding$494.5M$494.5M$494.5M$494.5M$480.4M
Balance sheet
20252024202320222021
Cash and short-term investments$4.9M$7.96M$11.6M$16.4M$60K
Net receivables$0.00$150K$60K$30K$10K
Inventory$0.00$0.00-$-60K-$-30K$0.00
Total current assets$4.9M$8.11M$11.6M$16.4M$70K
Property, plant and equipment, net$760K$230K$890K$1.46M$80K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$850K$320K$1M$1.57M$270K
Total assets$5.76M$8.44M$12.6M$18M$340K
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$310K$60K$440K$820K$3.68M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$660K$190K$610K$580K$4.34M
Long-term debt$230K$30K$30K$360K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$230K$30K$30K$360K$0.00
Capital lease obligations$230K$90K$460K$770K$0.00
Total liabilities$900K$220K$630K$940K$4.34M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-25.2M-$-21.62M-$-17.32M-$-11.44M-$-4M
Accumulated other comprehensive income (loss)-$-60K-$-50K-$-90K$0.00$0.00
Total equity$4.86M$8.22M$12M$17.1M-$-4M
Total investments$2.48M$5M$10M$10M$0.00
Total debt$540K$90K$460K$770K$3.68M
Net debt-$-1.87M-$-2.88M-$-1.1M-$-5.65M$3.62M
Cash flow statement
20252024202320222021
Net income-$-3.58M-$-4.36M-$-5.87M-$-7.45M-$-1.35M
Depreciation and amortization$390K$750K$770K$600K$30K
Stock-based compensation$240K$450K$930K$2.76M$0.00
Change in working capital$20K-$-590K-$-510K-$-1.02M$550K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-3.11M-$-4M-$-4.96M-$-5.27M-$-770K
Investments in property, plant and equipment-$-150K-$-10K-$-30K-$-780K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$2.69M$5.24M$60K-$-10.78M$0.00
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$0.00$100K$130K$22.4M$440K
Net change in cash-$-540K$1.4M-$-4.85M$6.36M-$-330K
Cash at end of period$2.42M$2.96M$1.56M$6.42M$60K
Operating cash flow-$-3.11M-$-4M-$-4.96M-$-5.27M-$-770K
Capital expenditure-$-150K-$-10K-$-30K-$-780K$0.00
Free cash flow-$-3.27M-$-4.01M-$-4.99M-$-6.05M-$-770K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Regencell Bioscience Holdings Limited

        Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

        CEO
        Yat-Gai Au
        Employees
        10
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Regencell Bioscience Holdings Limited (RGC)?

        InvestorsCraft does not currently publish an intrinsic value for RGC. How the IC value is calculated.

        Is RGC undervalued?

        InvestorsCraft does not publish an undervaluation signal for RGC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.